Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OKs Medtronic's Melody HDE In First Transcatheter Valve Approval

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's Melody percutaneous pulmonary heart valve is the first transcatheter heart valve available in the U.S. following FDA humanitarian device exemption approval, announced Jan. 25

You may also be interested in...



ACC Wrap-Up: Melody, MADIT-CRT, And More

New results were reported on heart valves, cardiac rhythm management devices, and biodegradable coronary stents at the 2014 American College of Cardiology Scientific Sessions in Washington, D.C.

Future Of Renal Denervation On Trial At ACC 2014 This Weekend

The full results of Medtronic’s SYMPLICITY HTN-3 trial, to be presented at the American College of Cardiology Scientific Sessions on March 29, could determine the fate of the renal denervation devices under development by several major companies for drug-resistant hypertension.

FDA, Industry Seek Better Computer Models For Cardio Device Development

FDA wants to better understand computer modeling methods - such as programs that simulate the performance of heart valves in the body - and help companies incorporate such tests into pre-market device applications

Related Content

Topics

UsernamePublicRestriction

Register

MT028435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel